Tel Aviv - Delayed Quote ILA

OPKO Health, Inc. (OPK.TA)

443.60

-3.50

(-0.78%)

At close: May 11 at 3:49:22 PM GMT+3

OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands

Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.

Zacks 10 days ago

OPK

ITGR

EHC
Q1 2025 OPKO Health Inc Earnings Call

Q1 2025 OPKO Health Inc Earnings Call

Thomson Reuters StreetEvents 10 days ago

OPK

PFE

LH
OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...

OPKO Health Inc (OPK) navigates a challenging quarter with strategic asset sales, cost-saving measures, and promising developments in its pharmaceutical pipeline.

GuruFocus.com 10 days ago

OPK

LH

PFE
OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for OPKO Health (OPK) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 11 days ago

OPK
OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates

OPKO Health (OPK) delivered earnings and revenue surprises of -66.67% and 8.87%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 11 days ago

OPK
OPKO Health: Q1 Earnings Snapshot

MIAMI (AP) — Opko Health Inc. OPK) on Wednesday reported a loss of $67.6 million in its first quarter. On a per-share basis, the Miami-based company said it had a loss of 10 cents.

Associated Press Finance 11 days ago

OPK
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference’s laboratory t

GlobeNewswire 11 days ago

OPK
Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround

OPKO Health (OPK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 19 days ago

OPK
OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages p

GlobeNewswire 24 days ago

OPK
OPKO Health, Inc. (NASDAQ:OPK) boasts of bullish insider sentiment with 52% ownership and they have been buying lately

Key Insights OPKO Health's significant insider ownership suggests inherent interests in company's expansion The top 3...

Simply Wall St. 25 days ago

OPK
NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today provided an update on the impact of current United States/China tariffs on its e-Commerce development program as a result of China's escalation in tariffs placed on US-produced goods imported into the country. This condition is expected to have a material impact on anticipated sales of US products into China.

PR Newswire 30 days ago

NXPL

NXPLW

OPK
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company’s existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO’s common stock has been repurchased under the existing program since its authorization in July 2024. “We believe OPKO’s shares continue to be significantly undervalued and offer an a

GlobeNewswire last month

OPK
Here's Why You Should Retain OPKO Health Stock in Your Portfolio

OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.

Zacks last month

OPK
Chairman & CEO of OPKO Health Phillip Frost Buys More Stock

Investors who take an interest in OPKO Health, Inc. ( NASDAQ:OPK ) should definitely note that the Chairman & CEO...

Simply Wall St. last month

OPK
Opko and Entera focus on oral care for obesity and metabolic disorders

Opko will hold 60% and Entera 40% ownership interests in the programme.

Pharmaceutical Technology last month

ENTX

OPK
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO’s proprietary long-acting oxyntomodulin analog

GlobeNewswire last month

OPK

ENTX
Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More.

We are maintaining our Buy rating on shares of Vertical Aerospace and our $13.50 price target. Vertical still boasts the second-largest aircraft backlog in the industry and remains the lone European survivor among electric vertical takeoff and landing, or eVTOL, competitors, providing the company an enviable competitive moat, considering that American competitors won’t be able to export initial FAA powered lift-certified aircraft to the region for some time. With the return of former (aircraft lessor) Avolon CEO Domhnal Slattery as chairman, we expect to see meaningful conversions of bankrupt competitors’ backlogs (particularly Lilium bizjet/luxury charter and airline shuttle customers) to Vertical’s backlog, which should ultimately result in an uptick in firm orders....It is apparent that the company will require additional capital that we have contemplated in our estimated discounted cash flow through 2035, which also includes revenue assumptions for aftermarket battery sales and service (Some 420 million pounds by 2035).

Barrons.com last month

TSLA

OPK

CXM
Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now?

We recently compiled a list of the 10 Best Stocks Under $3 to Buy Now. In this article, we are going to take a look at where OPKO Health, Inc. (NASDAQ:OPK) stands against the other stocks under $3. Investors are grappling with Trump-fueled stock market volatility in 2025. On March 12, 2025, Yahoo Finance reported […]

Insider Monkey last month

OPK
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK

LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.

Zacks last month

LH

OPK
Labcorp to acquire certain assets of Opko Health’s BioReference Health

Labcorp (LH) and OPKO Health (OPK) announced earlier on Tuesday that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health’s laboratory testing businesses focused on oncology and oncology-related clinical testing services across the United States. This transaction includes certain customer accounts and other operating assets. When complete, the t

TipRanks last month

OPK

LH

Performance Overview

Return	OPK.TA	S&P 500 (^GSPC)
YTD	-17.55%	-3.77%
1-Year	-4.58%	+8.37%
3-Year	-55.54%	+43.83%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

OPKO Health, Inc. (OPK.TA)

OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands

Q1 2025 OPKO Health Inc Earnings Call

OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ...

OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say

OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates

OPKO Health: Q1 Earnings Snapshot

OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results

Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround

OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025

OPKO Health, Inc. (NASDAQ:OPK) boasts of bullish insider sentiment with 52% ownership and they have been buying lately

NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

Chairman & CEO of OPKO Health Phillip Frost Buys More Stock

Opko and Entera focus on oral care for obesity and metabolic disorders

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More.

Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now?

Labcorp is Set to Acquire Select Assets of BioReference Health of OPK

Labcorp to acquire certain assets of Opko Health’s BioReference Health

Performance Overview